FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Psychedelic Drug Stocks Soar as Trump Orders FDA to Expedite Approvals
Vertical Aerospace (EVTL) Stock Plunges 10% Following $850M Financing Agreement
Morgan Stanley Picks Memory Makers Micron and Sandisk Over Intel (INTC) and AMD (AMD) for AI Exposure
As the film, "The Story of Everything," Explores the Nature of Reality, a New Book from Oaklea Press Argues: "You Are Not Your Brain"- and That Changes Everything
Milei’s Auction of Argentine Railroads Risks Sidelining US-Backed Bidder
US Homebuilders Set for Another ‘Lost’ Earnings Season
Propane Education & Research Council Commits $6 Million to Nexio to Advance Propane Commercial Vehicle Certification
NeutronX Secures CAGE Code; Launches Federal Bidding Strategy Positioning NextNRG (NASDAQ: NXXT) to Target U.S. Energy Security and Infrastructure Contracts
OT Security Experts Warn: Your Team Isn't the Problem. Your Architecture Is.
Inside one of Amsterdam’s first supervised self-driving Teslas
Abu Dhabi’s Zayed airport opens for non-flying shoppers
NYSE Content Update: SEC Chair Paul Atkins to Ring Opening Bell at NYSE
Revolut Aims for $150 Billion Valuation Ahead of IPO
T-Mobile US Enhances Partnership with Rogers Communications
Delta Air Lines Shares Surge 84% Over Past Year
CenterWell Launches Fulfillment Index to Define Aging Well
Mastercard Integrates AI Payment Solutions to Enhance Digital Commerce Trust
Shell Negotiates Sale of South African Fuel Retail Business to ADNOC
Apple 'Relatively Insulated' From AI Volatility, Analyst Says
Kuwait Announces Force Majeure on Oil Shipments Amid Hormuz Disruptions
USA Rare Earth to Buy Brazilian Miner in $2.8 Billion Deal
Affiliates of Blue Owl to buy healthcare REIT Sila Realty Trust for $2.4 Billion
Canada’s annual CPI rises to 2.4% as Iran war spikes gasoline costs
Nakheel awards $144m Dubai Islands infrastructure contract
AI surges as focus for strategic planning
NATO'S RUTTE TO MEET ERDOGAN IN ANKARA APR. 21-22...
CaixaBank Plans 60% Workforce Expansion in London
AST SpaceMobile Shares Decline Following Satellite Deployment Error
Canada's March Inflation Rate Rises to 2.4% Amid Energy Price Surge
AST SpaceMobile Stock Declines Following Satellite Loss in Blue Origin Launch
Accenture Collaborates with Avanade and Microsoft on AI Factory Intelligence System
PayPay Corporation Debuts on Nasdaq, Marking Key Development for Japanese Tech Sector
Study Highlights Predictive Value of Ignite Proteomics' RPPA Platform for Breast Cancer Therapy
GE Vernova Faces Legal Challenges Amid Growing Energy Sector Demand
Worthington Steel Achieves Top Supplier Rating from John Deere for 14th Year
Gogo Faces Diverging Analyst Opinions Amid Guidance Changes
Morgan Stanley Increases Intel Price Target Amid Stronger Server Demand
SLB Adjusts Fair Value Estimate Amid Analyst Target Revisions
Late April Declared Optimal Time for Home Listings in the U.S.
Novo Nordisk Launches DKK 15 Billion Share Repurchase Programme
Debate Emerges Over SpaceX IPO Valuation
U.S. Government to Refund $166 Billion in Tariffs Following Supreme Court Ruling
Iran War Inflation Likely To Stick Even After Ceasefire, Economists Say
Canadian Strategic Missions Corporation to lead $3 million government-backed project to advance manufacturing for nuclear micro-reactors
Canada Inflation Jumps to 2.4% as Iran War Drives Up Gas Prices
Ed Miliband unveils move to delink gas and electricity prices
Accenture's New Agentic Factory System Debuts With Microsoft
Bristow Group Announces Planned Retirement of Chief Operating Officer, Government Services
CD&R-backed Multi-Color secures court approval for $4bn debt overhaul
FDA Grants Priority Review for PADCEV and Keytruda Combination in Bladder Cancer Treatment
Astellas Pharma Inc. and Pfizer Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Priority Review. The application seeks approval for the use of PADCEV (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) as a perioperative treatment for muscle-invasive bladder cancer, regardless of a patient's eligibility for cisplatin.
PADCEV is an antibody-drug conjugate that targets Nectin-4, while Keytruda is a PD-1 inhibitor. This combination aims to improve treatment outcomes for patients undergoing surgery for muscle-invasive bladder cancer. The FDA's Priority Review designation is granted to therapies that may offer significant improvements in safety or effectiveness over existing treatments, expediting the review process.
The acceptance of this application reflects the ongoing efforts to enhance treatment options for patients with bladder cancer, a condition that often requires aggressive management strategies. Astellas and Pfizer are committed to advancing innovative therapies that address unmet medical needs in oncology.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News